News | December 09, 2024
Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
